Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19833066 | 0.91 | CDK1 (0.31) | CDK2CDK1 | |
| SCHEMBL21101702 | 0.85 | CCNE2 (0.36) | CCNE2CCNE1CDK2 | |
| SCHEMBL21101704 | 0.85 | CCNE2 (0.36) | CCNE2CCNE1CDK2 | |
| SCHEMBL22889225 | 0.85 | CCNE2 (0.31) | CCNE2CCNE1CDK2 | |
| SCHEMBL19644850 | 0.84 | ADORA3 (0.38) | CCNE1CDK2CDK1 | |
| SCHEMBL19833093 | 0.84 | ADORA3 (0.38) | CCNE1CDK2CDK1 | |
| SCHEMBL22224853 | 0.84 | CDK1 (0.30) | CDK2CDK1 | |
| SCHEMBL21101711 | 0.83 | CCNE2 (0.34) | CCNE2CCNE1CDK2 | |
| SCHEMBL19827964 | 0.80 | CCNE2 (0.38) | CCNE2CCNE1CDK2CDK1 | |
| SCHEMBL19644706 | 0.80 | CDK2 (0.49) | CCNE2CCNE1CDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000523-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180030081-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030081-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | CCNE2 3057/4885CCNE1 3354/4885CDK2 1661/4885 |
| US-10000523-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | NSUN2, PNP, NUDT1 | CCNE2 3886/4885CCNE1 4041/4885CDK2 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.